Davita Inc vs Snowflake Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Snowflake Inc trades at $345.15 (market cap $117.43B). The key difference: Snowflake Inc is far larger — about 10.4× Davita Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Snowflake Inc for 54 Days on average.
| DVA | SNOW | |
|---|---|---|
Market Cap | $11.28B | $117.43B |
Volume | 650,294 | 2,441,528 |
Sector | Health | Technology |
52-Week High | $240.96 | $356.47 |
52-Week Low | $103.87 | $121.11 |
Typical Hold Time | 113 Days | 54 Days |
Enterprise Value | $24.00B | $117.85B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
SNOW trades at $343.4, up 2.22% on the day, with a neutral technical signal and bullish moving averages. Revenue growth is strong, reaching $3.63B in 2025, but the company remains unprofitable with a net income margin of -20.07%. Recent news highlights a $3.75B convertible note offering and positive analyst coverage, with 81% of analysts rating it a Buy and a consensus price target of $418.03.
The outlook is mixed: robust revenue expansion and strategic partnerships offer upside, but persistent losses, high valuation multiples, and dilution risks from the note issuance pose significant challenges. Investor sentiment is cautiously optimistic, hinging on future profitability improvements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →